Kim, Kwangmeyung Professor
Pharmaceutical Sciences/Industrial Pharmaceutical Science/Division of Pharmacy
Dr. Kwangmeyung Kim, affiliated with the College of Pharmacy (Graduate School of Pharmaceutical Sciences), is a professor who has been conducting research on nanomedicines for diagnosis and treatment of intractable diseases. He obtained his bachelor's and master's/doctoral degrees from Sungkyunkwan University and Gwangju Institute of Science and Technology (GIST), respectively, and had worked at the Korea Institute of Science and Technology (KIST) to develop various nanomedicines for microenvironment-specific diagnosis, drug delivery, and immunotherapy of intractable diseases such as malignant tumors. Throughout his research, more than 300 papers have been published including Advanced Materials, Advanced Functional Materials, ACS Nano, Angewandte Chemie, and JACS, and he has been selected as one of the top 1% of citations by Thomson Reuters for five consecutive years. Appointed to the College of Pharmacy at Ewha Womans University in 2022, he is conducting a wide range of research about discovery, synthesis, in vitro and in vivo evaluation, and preclinical studies of various nanomedicine candidates based on a high-level research infrastructure.
- University-Industry Cooperation Building #523-3
- 02-3277-2466
- Research Interests
- Theranostics, Nanomedicine, Prodrug, Immunotherapy
Research Record
- Recent developments in chemodrug-loaded nanomedicines and their application in combination cancer immunotherapy Journal of Pharmaceutical Investigation, 2024, v.54 no.1, 13-36
- Adoptive Transfer of Photosensitizer-Loaded Cytotoxic T Cells for Combinational Photodynamic Therapy and Cancer Immuno-Therapy Pharmaceutics, 2023, v.15 no.4, 1295
- All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy Bioactive Materials, 2023, v.28, 358-375
- Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy PHARMACEUTICS, 2023, v.15 no.2, 411
- Enhanced delivery of the phototherapeutic nanoparticles via hepatocyte overload Colloids and Surfaces B: Biointerfaces, 2023, v.221, 112959
- Fluorescence-Based Mono- and Multimodal Imaging for In Vivo Tracking of Mesenchymal Stem Cells Biomolecules, 2023, v.13 no.12, 1787
- In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy Biomaterials, 2023, v.295, 122038
- In vivo toxicity evaluation of tumor targeted glycol chitosan nanoparticles in healthy mice: repeated high-dose of glycol chitosan nanoparticles potentially induce cardiotoxicity JOURNAL OF NANOBIOTECHNOLOGY, 2023, v.21 no.1, 82
- Intracellular Glucose-Depriving Polymer Micelles for Antiglycolytic Cancer Treatment Advanced Materials, 2023, v.35 no.10, 2207342
- Micro-syringe chip-guided intratumoral administration of lipid nanoparticles for targeted anticancer therapy Biomaterials Research, 2023, v.27 no.1, 102
- Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors International Journal of Molecular Sciences, 2023, v.24 no.12, 10082
- Recent Studies and Progress in the Intratumoral Administration of Nano-Sized Drug Delivery Systems Nanomaterials, 2023, v.13 no.15, 2225
- Thermally Managed, Injectable Optoelectronic Probe with Heat Dissipation Guide for Photodynamic Therapy Small, 2023, v.19 no.35, 2300753
- Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy Biomaterials, 2022, v.289, 121806
- Implantable micro-scale LED device guided photodynamic therapy to potentiate antitumor immunity with mild visible light Biomaterials Research, 2022, v.26 no.1, 56
- Injectable Hydrogel-Based Combination Cancer Immunotherapy for Overcoming Localized Therapeutic Efficacy Pharmaceutics, 2022, v.14 no.9, 1908
- Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity Biomaterials, 2022, v.290, 121841
- Mesenchymal Stem Cell-Mediated Deep Tumor Delivery of Gold Nanorod for Photothermal Therapy Nanomaterials, 2022, v.12 no.19, 3410
- Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy Journal of Controlled Release, 2022, v.351, 713-726
- Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity Journal of Nanobiotechnology, 2022, v.20 no.1, 436
- Prediction the clinical EPR effect of nanoparticles in patient-derived xenograft models Journal of Controlled Release, 2022, v.351, 37-49
- Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy PHARMACEUTICS, 2022, v.14 no.10, 2131
- [학술지논문] Thermally Managed, Injectable Optoelectronic Probe with Heat Dissipation Guide for Photodynamic Therapy SMALL, 2023, v.19 no.35 , 202300-202300
- [학술지논문] Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy BIOMATERIALS, 2022, v.289 no.0 , 121806-121806
- [학술지논문] Copper-Free Click Chemistry: Applications in Drug Delivery, Cell Tracking, and Tissue Engineering ADVANCED MATERIALS, 2022, v.34 no.10 , 2107192--
- [학술지논문] Light-triggered photodynamic nanomedicines for overcoming localized therapeutic efficacy in cancer treatment ADVANCED DRUG DELIVERY REVIEWS, 2022, v.186 no.- , 114344--
- [학술지논문] Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity BIOMATERIALS, 2022, v.290 no.0 , 121841-121841
- [학술지논문] Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery ADVANCED DRUG DELIVERY REVIEWS, 2022, v.183 no.- , 114177--
- [학술지논문] Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity BIOMATERIALS, 2021, v.272 no.- , 120791--
- [학술지논문] Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models via non-invasive fluorescence molecular tomography BIOMATERIALS, 2021, v.266 no.- , 120472--
- [학술지논문] The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis Biomaterials, 2021, v.279 no.- , 121189--
- [학술지논문] Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy ACS NANO, 2021, v.15 no.7 , 12086-12098
Courses
-
2024-1st
-
Drug Delivery System
- Subject No 36213Class No 01
- 5Year ( 1.5Credit , 1.5Hour) Thu 4~4 (POSCO552)
- Major Requisite
-
Drug Delivery System
- Subject No 36213Class No 02
- 5Year ( 1.5Credit , 1.5Hour) Thu 5~5 (POSCO552)
- Major Requisite
-
Drug Delivery System
- Subject No 36213Class No 03
- 5Year ( 1.5Credit , 1.5Hour) Wed 5~5 (PHM-A400)
- Major Requisite
-
Honors research
- Subject No 37803Class No 01
- 4Year ( 1Credit , 1Hour)
-
Introduction to Pharmaceutical Research
- Subject No 38940Class No 01
- 2Year ( 1.5Credit , 1.5Hour) Thu 6~6 (PHM-A404)
- Major Requisite
-
Advanced Topics in Biotherapeutics Delivery
- Subject No G16857Class No 01
- Year ( 3Credit , 3Hour) Mon 5~6 (PHM-)
-
-
2023-2nd
-
Advanced Pharmacy Practice and Research I 강의 계획서 상세보기
- Subject No 37154Class No 01
- 6Year ( 4Credit , 200Hour)
- Major Requisite
-
Advanced Pharmacy Practice and Research Ⅱ 강의 계획서 상세보기
- Subject No 37155Class No 01
- 6Year ( 4Credit , 200Hour)
- Major Requisite
-
Advanced Pharmacy Practice and Research Ⅲ 강의 계획서 상세보기
- Subject No 37156Class No 01
- 6Year ( 4Credit , 200Hour)
- Major Requisite
-
Honors research
- Subject No 37803Class No 01
- 4Year ( 1Credit , 1Hour)
-
Seminar for Pharmaceutical Sciences II
- Subject No G16888Class No 01
- Year ( 3Credit , 3Hour) Thu 7~8 (PHM-A400)
-
Seminar for Pharmaceutical Sciences Ⅱ
- Subject No G18239Class No 01
- Year ( 3Credit , 3Hour) Thu 7~8 (PHM-A400)
-
-
2023-1st
-
Drug Delivery System
- Subject No 36213Class No 01
- 5Year ( 1.5Credit , 1.5Hour) Thu 4~4 (POSCO552)
- Major Requisite
-
Drug Delivery System
- Subject No 36213Class No 02
- 5Year ( 1.5Credit , 1.5Hour) Thu 3~3 (POSCO552)
- Major Requisite
-
Drug Delivery System
- Subject No 36213Class No 03
- 5Year ( 1.5Credit , 1.5Hour) Wed 4~4 (PHM-A400)
- Major Requisite
-
Drug Delivery System
- Subject No 36213Class No 04
- 5Year ( 1.5Credit , 1.5Hour) Wed 4~4 (PHM-A400)
- Major Requisite
-
Introduction to Pharmaceutical Research 강의 계획서 상세보기
- Subject No 39045Class No 01
- 2Year ( 1.5Credit , 1.5Hour) Thu 6~6 (PHM-)
-
Advanced Topics in Biotherapeutics Delivery
- Subject No G16857Class No 01
- Year ( 3Credit , 3Hour) Mon 5~6 (PHM-)
-
-
2022-2nd
-
Seminar for Pharmaceutical Sciences IV
- Subject No G16889Class No 01
- Year ( 3Credit , 3Hour) Thu 7~8 (PHM-A400)
- Professor Determined
-
Seminar for Pharmaceutical Sciences Ⅳ
- Subject No G18241Class No 01
- Year ( 3Credit , 3Hour) Thu 7~8 (PHM-A400)
- Professor Determined
-